In brief
A medicine may be eligible for Medicare drug coverage for a non-weight-loss use without every plan agreeing to pay.
Ask about the proposed product and the actual reason it would be prescribed. Do not change that reason to fit a coverage rule.
Learn the plan’s terms
The plan’s covered-drug list is called its formulary; with prior authorization, the insurer must agree before you fill the prescription.
Ask whether the medicine is on that list for the proposed use. Then ask about approval steps, your share of the bill and any separate visit or test costs.
Request the answer in writing where possible. Keep a service’s estimate separate from the plan’s own answer.
Medicare’s temporary weight-care programme
Medicines used solely to lose weight remained excluded from ordinary Medicare Part D drug benefits as of September 26, 2026.
The GLP-1 Bridge was a temporary Medicare payment programme, separate from ordinary Part D insurance. For eligible participants, a month’s supply of a weight-care medicine included in the programme cost $50.
GLP-1 names a hormone involved in controlling appetite and blood sugar, and medicines that copy the hormone’s effects.
The programme’s start date was July 1, 2026 and its end date was December 31, 2027, according to the terms reviewed on September 26, 2026.
Who could use the Bridge?
Adults aged 18 and above met the age requirement, which listed no maximum age; age 80 alone did not exclude a person.
The health rules used body mass index, or BMI, a measure based on weight and height when treatment began.
The weight rule was met at a BMI of 35 or above without any listed extra health condition.
For a BMI of 30 or above, the qualifying conditions were kidney disease from stage 3a onwards, high blood pressure that remained uncontrolled, or a specific form of heart failure.
The heart-failure rule required the type with preserved pumping strength; your doctor can check the exact diagnosis in the programme’s medical list.
Ask your doctor to check that exact diagnosis and your kidney-disease stage in your records, if either condition applies to you.
The blood-pressure requirement was a top reading greater than 140 or a bottom reading greater than 90 despite taking two blood-pressure medicines.
For a BMI of 27 or above, the listed conditions included artery disease with limb symptoms, a previous stroke or heart attack, or pre-diabetes.
Ask the person writing the prescription to check your measurements and exact diagnosis against the official list in the source file.
The programme required a prescription, approval before filling it, and ongoing structured help with eating and physical activity.
Enrollment had to be in either a stand-alone drug plan under Part D or a Medicare Advantage plan whose drug coverage qualified; certain plan types were excluded.
A person was ineligible for the Bridge in 2026 if their Part D plan had previously covered a GLP-1 drug during that year.
Those with type 2 diabetes were told to use regular Part D coverage rather than the Bridge.
The liver exclusion applied to a specific diagnosis with liver inflammation and substantial scarring, not to every liver condition.
Ask your doctor to check that diagnosis and any sleep or heart conditions against the official exclusions too.
Check the medicine and payment rules
The included products were orforglipron under the Foundayo name, Wegovy (semaglutide) in injection or tablet form, and the KwikPen version of Zepbound (tirzepatide).
Other Zepbound pens and vials were left out.
The Bridge’s $50 payment did not count towards the yearly limit on what you personally spend for medicines covered by Part D.
It did not count towards your Part D deductible either: the sum you must pay before the plan starts contributing.
The Bridge gave no extra reduction for people on low incomes, and coupons could not reduce its $50 payment.
Take these checks to the person writing the prescription and your drug plan. Ask them to check the official programme details in the source file before counting on that price.
Keep state programmes separate
As of September 26, 2026, Medicaid, the state-run health programme, covered weight-care medicines differently from state to state.
A separate programme called BALANCE let states choose to join an arrangement for negotiated medicine prices and coverage terms.
An announcement about BALANCE did not mean your state had joined or that your medicine was covered.
Ask your own plan or state programme about the exact medicine and use. An announcement about another programme does not answer that question.